Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses - PubMed
4 hours ago
- #mucosal-vaccine
- #zoonotic-spillover
- #H5N1
- Nasal RNA-scaffold-protein vaccine (RSPVac) protects mice from lethal H5N1 clade 2.3.4.4b infection.
- RSPVac induces strong antibody responses in serum and mucosa, along with mucosal antigen-specific T cells.
- Vaccinated animals showed complete protection against vaccine-matched avian virus challenges without pathological signs.
- Protection was also observed against vaccine-unmatched H1N1 and H7N9 challenges, indicating broad efficacy.
- RSPVac induces a controlled immune activation with transient cytokine expression and regulatory neutrophils.
- Mutant RSPVac showed impaired vaccination outcomes, suggesting a complex activation mechanism.
- The study highlights RSPVac's potential as a non-infectious mucosal vaccine to prevent zoonotic virus transmission.